<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">This study is a prospective, multicentre, randomised, double-blinded, parallel, superiority, placebo-controlled trial (1:1). Patients will be randomised after completion of chemotherapy. Patients who were expected to develop prolonged (&gt; 7 days) neutropenia will be randomised to receive a prophylactic solution of taurolidine-citrate-heparin using the lock technique (study group) or a solution with heparin alone using the same technique (placebo group). The study will be conducted in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) recommendations [
 <xref ref-type="bibr" rid="CR32">32</xref>], Additional file 
 <xref rid="MOESM1" ref-type="media">1</xref>.
</p>
